Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China.

CONCLUSION: Treatment with DUAL provides significant clinical benefit, while accruing lower lifetime costs.
PMID: 29860879 [PubMed - as supplied by publisher]

Source: Journal of Comparative Effectiveness Research - June 6, 2018 Category: General Medicine Tags: J Comp Eff Res Source Type: research